Boehringer Ingelheim

3 standout digital innovations in pharma this year
3 standout digital innovations in pharma this year
Pharma Voice
IDEA Pharma
innovation
digital pharma
AstraZeneca
Roche
Boehringer Ingelheim
Flag link:
Boehringer Ingelheim to collaborate with Phenomic AI on stroma-rich cancers
Boehringer Ingelheim to collaborate with Phenomic AI on stroma-rich cancers
Medical Marketing and Media
Boehringer Ingelheim
artificial intelligence
Phenomic AI
stroma-rich cancers
Flag link:
Boehringer plugs in IBM-trained AI model to boost antibody drug discovery efforts
Boehringer plugs in IBM-trained AI model to boost antibody drug discovery efforts
Fierce Biotech
Boehringer Ingelheim
artificial intelligence
IBM
machine learnings
drug discovery
Flag link:
Skyrizi goes sky-high in October among Rx, OTC pharma brands
Skyrizi goes sky-high in October among Rx, OTC pharma brands
Medical Marketing and Media
Boehringer Ingelheim
AbbVie
Skyrizi
DTC advertising
pharma advertising
Flag link:
Boehringer clears blues to go green, unveiling new corporate branding to convey 'unwavering optimism'
Boehringer clears blues to go green, unveiling new corporate branding to convey 'unwavering optimism'
Fierce Pharma
Boehringer Ingelheim
branding
Flag link:
AbbVie, AstraZeneca, Boehringer and more face FTC's ire for 'improper' patent listings
AbbVie, AstraZeneca, Boehringer and more face FTC's ire for 'improper' patent listings
Fierce Pharma
FTC
Orange Book
patents
AbbVie
AstraZeneca
Boehringer Ingelheim
Flag link:
EU Commission fines pharma companies for price fixing
EU Commission fines pharma companies for price fixing
Reuters
Europe
API
price fixing
antitrust
Alkaloids
Linnea
Boehringer Ingelheim
Transo-Pharm
Flag link:
Chasing Boehringer, Anaptys hits goal in pivotal rare skin disease trial, plans out-licensing deal
Chasing Boehringer, Anaptys hits goal in pivotal rare skin disease trial, plans out-licensing deal
Fierce Biotech
AnaptysBio
generalized pustular psoriasis
clinical trials
imsidolimab
Boehringer Ingelheim
Flag link:
Boehringer moves obesity therapy into phase 3
Boehringer moves obesity therapy into phase 3
Pharmaphorum
Boehringer Ingelheim
Zealand Pharma
clinical trials
obesity
survodutide
Flag link:
Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar
Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar
Fierce Pharma
Boehringer Ingelheim
Cyltezo
biosimilars
Humira
drug pricing
Flag link:
Boehringer launches 81% discounted biosimilar of AbbVie's Humira
Boehringer launches 81% discounted biosimilar of AbbVie's Humira
Reuters
Boehringer Ingelheim
biosimilars
AbbVie
Humira
unbranded biosimilars
Flag link:
FDA greenlights Jardiance for treating chronic kidney disease
FDA greenlights Jardiance for treating chronic kidney disease
Medical Marketing and Media
Eli Lilly
Boehringer Ingelheim
Medicare
Jardiance
FDA
chronic kidney disease
Flag link:
Biden administration lists 10 drugs for Medicare price negotiation
Biden administration lists 10 drugs for Medicare price negotiation
Medical Marketing and Media
Medicare
HHS
Pfizer
Bristol Myers Squibb
Eli Lilly
Boehringer Ingelheim
AstraZeneca
AbbVie
Novo Nordisk
JNJ
drug pricing
Flag link:
Boehringer Ingelheim Joins Legal Battle Against IRA Drug Pricing Provisions
Boehringer Ingelheim Joins Legal Battle Against IRA Drug Pricing Provisions
BioSpace
Boehringer Ingelheim
drug pricing
legal
Medicare
Inflation Reduction Act
Flag link:
Boehringer preps phase 3 for dual-action obesity drug
Boehringer preps phase 3 for dual-action obesity drug
Pharmaphorum
Boehringer Ingelheim
clinical trials
obesity
survodutide
Flag link:
The 10 drugs that CMS might wrangle into negotiations
The 10 drugs that CMS might wrangle into negotiations
Beckers Hospital Review
CMS
Medicare
drug pricing
Bristol Myers Squibb
Janssen
Merck
Pfizer
Amgen
Boehringer Ingelheim
Pharmacyclics
AstraZeneca
Astellas
GSK
Flag link:
Spotlight – Nash in 2023 and beyond
Spotlight – Nash in 2023 and beyond
EP Vantage
NASH
Boehringer Ingelheim
Zealand Pharma
Akero Therapeutics
Axcella Health
Eli Lilly
Pfizer
Ionis Pharmaceuticals
Cascade
AstraZeneca
Gilead Sciences
Novo Nordisk
Ascletis Pharma
MediciNova
Flag link:
Boehringer Ingelheim posts more Jardiance growth as potential US kidney disease approval nears
Boehringer Ingelheim posts more Jardiance growth as potential US kidney disease approval nears
Fierce Pharma
Boehringer Ingelheim
Jardiance
diabetes
earnings
Flag link:
Biosimilar makers split strategies in bid to take on top-selling Humira
Biosimilar makers split strategies in bid to take on top-selling Humira
BioPharma Dive
biosimilars
Humira
AbbVie
rebates
drug pricing
Amgen
Celltrion
Novartis
Boehringer Ingelheim
Biocon
Fresenius
Sandoz
Organon
Coherus
Flag link:
AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis
AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis
Fierce Pharma
AbbVie
Skyrizi
Amgen
Otezla
Boehringer Ingelheim
psoriasis
Flag link:

Pages